See Shionogi-Sponsored Publications
Publications
Here, you can review available Shionogi-sponsored publications. If you would like an electronic copy of one of the journal publications on this page, please contact
Shionogi Medical Information for further assistance.
Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses of products will receive FDA approval. Shionogi does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
Effect of cefiderocol, a siderophore cephalosporin, on QT/QTc interval in healthy adult subjects
Effect of cefiderocol, a siderophore cephalosporin, on QT/QTc interval in healthy adult subjects
Genetic association of phosphodiesterases with human cognitive performance
Genetic association of phosphodiesterases with human cognitive performance
In vitro activity of cefiderocol, a siderophore cephalosporin, against Gram-Negative bacilli isolated by clinical laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015
In vitro activity of cefiderocol, a siderophore cephalosporin, against Gram-Negative bacilli isolated by clinical laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015
Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects
Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects
Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial
Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial